Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?

Bone Marrow Transplantation

Volumn 29, Issue 10, 2002, Pages 853-859

  Mehta, J ^a   Powles, R ^a   Sirohi, B ^a   Treleaven, J ^a   Kulkarni, S ^a   Saso, R ^a   Tait, D ^a   Singhal, S ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acute myeloid leukemia; Allogeneic bone marrow transplantation; Blood group; Graft versus leukemia; Relapse

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; MELPHALAN; METHOTREXATE; PREDNISOLONE; THALIDOMIDE;

ACUTE DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; AGE; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD DONOR; BLOOD GROUP ABO INCOMPATIBILITY; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC DISEASE; CONTROLLED STUDY; FEMALE; GENDER; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LEUKEMIA REMISSION; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; RECIPIENT; RECURRENCE RISK; SIBLING; STATISTICAL ANALYSIS; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; WHOLE BODY RADIATION; ADOLESCENT; ADULT; ALLOTRANSPLANTATION; BLOOD; BLOOD GROUP ABO SYSTEM; BONE MARROW TRANSPLANTATION; DONOR; ERYTHROCYTE TRANSFUSION; HISTOCOMPATIBILITY; IMMUNOLOGY; MIDDLE AGED; REMISSION;

ABO BLOOD-GROUP SYSTEM; ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; ERYTHROCYTE TRANSFUSION; FEMALE; HISTOCOMPATIBILITY; HUMAN; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGE; REMISSION INDUCTION; SUPPORT, NON-U.S. GOV'T; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; HUMANS; MIDDLE AGED;

EID: 0035998361     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703545     Document Type: Article

References (27)

1. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts
2. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation
3. Graft-versus-leukemia reactions after bone marrow transplantation
4. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: A randomised trial
5. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers
6. Immunohematologic consequences of major ABO-mismatched bone marrow transplantation
7. Immunohematologic complications of bone marrow transplantation
8. Transfusion requirements after bone marrow transplantation from HLA-identical siblings: Effects of donor-recipient ABO incompatibility
9. ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation
10. Graft-versus-host disease and survival after ABO-incompatible allogeneic bone marrow transplantation: A single-centre experience
11. ABO-incompatible marrow transplants
12. ABH and Lewis antigen and antibody expression after bone marrow transplantation
13. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia
14. The relationship between donor-recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation from HLA-identical siblings
15. Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: Evidence for a graft-versus-plasma cell effect
16. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine
17. Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission
18. Melphalan, single-fraction total-body irradiation and allogeneic bone marrow transplantation for acute leukaemia: Review of transplant-related mortality
19. Melphalan versus cyclophosphamide with total body irradiation as conditioning for allogeneic bone marrow transplantation in first remission acute myeloid leukemia
20. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery after transplantation
21. Outcome of acute leukemia relapsing after bone marrow transplantation: Utility of second transplants and adoptive immunotherapy
22. Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: The inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse
23. ABO-incompatible bone marrow transplantation: The transfusion of incompatible plasma may exacerbate regimen-related toxicity
24. ABO compatibility and acute graft-versus-host disease following allogeneic bone marrow transplantation
25. Survival after ABO-incompatible allogeneic bone marrow transplant after a preparative regimen of busulfan and cyclophosphamide
26. Modulation of the T cell compartment by blood transfusion. Effect on cytotoxic and helper T lymphocyte precursor frequencies and T cell receptor Vbeta usage
27. NK cells can recognize asialylated autologous lymphocytes and ABO-mismatched lymphocytes